Cassava Sciences Inc SAVA:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 6:59 PM EDT
20.57quote price arrow down-0.17 (-0.82%)
Volume
8,518
Close
20.74quote price arrow up+0.19 (+0.92%)
Volume
471,816
52 week range
12.32 - 32.10
Loading...
  • Open20.68
  • Day High20.84
  • Day Low20.17
  • Prev Close20.55
  • 52 Week High32.10
  • 52 Week High Date12/12/23
  • 52 Week Low12.32
  • 52 Week Low Date10/13/23

Key Stats

  • Market Cap896.917M
  • Shares Out43.25M
  • 10 Day Average Volume1.23M
  • Dividend-
  • Dividend Yield-
  • Beta-0.35
  • YTD % Change-7.86

KEY STATS

  • Open20.68
  • Day High20.84
  • Day Low20.17
  • Prev Close20.55
  • 52 Week High32.10
  • 52 Week High Date12/12/23
  • 52 Week Low12.32
  • 52 Week Low Date10/13/23
  • Market Cap896.917M
  • Shares Out43.25M
  • 10 Day Average Volume1.23M
  • Dividend-
  • Dividend Yield-
  • Beta-0.35
  • YTD % Change-7.86

RATIOS/PROFITABILITY

  • EPS (TTM)-2.32
  • P/E (TTM)-8.94
  • Fwd P/E (NTM)-11.18
  • EBITDA (TTM)-104.427M
  • ROE (TTM)-53.27%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date04/29/2024(est)
  • Ex Div Date12/13/2010
  • Div Amount2.00
  • Split Date-
  • Split Factor-

Latest On Cassava Sciences Inc

 

Profile

MORE
Cassava Sciences, Inc. is a biotechnology company focused on Alzheimer's disease. The Company's science is based on stabilizing, but not removing, a critical protein in the brain. The Company is focused on its product discovery and development efforts on disorders of the nervous system. Its lead therapeutic drug candidate, simufilam, is under clinical evaluation for the proposed treatment of Alzheimer's disease dementia in Phase 3 clinical studies. The Company has two...
Remi Barbier
Chairman of the Board, President, Chief Executive Officer
Eric Schoen
Chief Financial Officer
Address
6801 N CAPITAL OF TEXAS HIGHWAY
BUILDING 1; SUITE 300
Austin, TX
78731
United States

Top Peers

SYMBOLLASTCHG%CHG
ETNB
89Bio Inc
8.58-0.34-3.81%
SPRY
ARS Pharmaceuticals Inc
8.26-0.24-2.82%
ELVN
Enliven Therapeutics Inc
17.49+0.12+0.69%
TYRA
Tyra Biosciences Inc
16.00-0.38-2.32%
ALXO
ALX Oncology Holdings Inc
16.22+0.72+4.65%